What factors drive you to prioritize treatments that inhibit T cells vs B cell depletion when choosing therapies for patients with refractory SLE?

Other than for immune cytopenias that are likely primarily autoAb mediated it is difficult to know the relative extent to which T cell vs humoral immunity effects lupus disease activity. As such, the main driver for me to target T-cell activation currently would be organ complications not known to b...